Brief: Herantis Pharma 2015 operating loss widens to EUR 16.2 million
25/02/2016 07:01
Feb 25 (Reuters) - Herantis Pharma Oyj HRTIS.HE :
* FY revenue 1,955 euros versus 800 euros year ago
* FY operating loss 16.2 million euros ($17.8 million)
versus 7.7 million euros
* Company does not expect any revenues in 2016
* AGM resolved that no dividend be paid for financial
period Jan. 1-Dec. 31, 2014
* Financial position is expected to be positive at end of
2016
* Main objectives for 2016 are recruiting first patients in
clinical trials with Lymfactin and CDNF
* Year ago objective has been set to enter
commercialization agreement for at least one of top priority
drugs with a Finnish or international pharmaceutical company by
end of 2017
Source text for Eikon: ID:nHUG2Pcg2P
Further company coverage: HRTIS.HE
($1 = 0.9071 euros)
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))